Physician profile
Rinu Abraham
NPI 1518353234
$93,711.87
in general payments reported to CMS, 2019-2025
16 companies · $2,647 in 2025
The $2,647 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $371 · 2021: $613 · 2022: $38.34 · 2023: $115 · 2024: $565 · 2025: $2,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $326.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $87,976.28 | 2019-2021 | |
| Tg Therapeutics, INC. | $3,036.74 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $676.73 | 2019-2025 | Ultomiris |
| Celgene Corporation | $638.34 | 2021-2022 | |
| Genzyme Corporation | $368.48 | 2019-2020 | |
| Emd Serono, INC. | $366.17 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $233.78 | 2019 | |
| Alnylam Pharmaceuticals INC. | $121.24 | 2019 | |
| Greenwich Biosciences, INC. | $101.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $90.99 | 2019 | |
| Lundbeck LLC | $46.18 | 2020 | |
| Portola Pharmaceuticals, LLC | $23.44 | 2019 | |
| Neurocrine Biosciences, INC. | $19.30 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.44 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rinu Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.